Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors
, , , , , , , , , , and
Feb 27, 2025
About this article
Article Category: research article
Published Online: Feb 27, 2025
Page range: 100 - 109
Received: Jan 23, 2025
Accepted: Feb 04, 2025
DOI: https://doi.org/10.2478/raon-2025-0017
Keywords
© 2025 Tim Wilke et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

FIGURE 2.

Response to percutaneous electrochemotherapy (pECT) treatment in the 2 groups
RESPONSE | i.v. pECT (N = 21) | i.a. pECT (N = 31) | P value | P value | ||
---|---|---|---|---|---|---|
N | % | N | % | Overall distribution | CR |
|
13 | 61.9% | 25 | 80.6% | 0.3454 | 0.1349 | |
5 | 23.8% | 4 | 12.9% | |||
1 | 4.8% | 0 | 0.0% | |||
0 | 0.0% | 1 | 3.2% | |||
2 | 9.5% | 1 | 3.2% |
Descriptive characteristics of the patients in the 2 groups
PATIENTS | i.v. pECT (N = 18) | i.a. pECT (n = 26) | P value | ||
---|---|---|---|---|---|
N | % | N | % | ||
|
8 | 44% | 15 | 58% | 0.5406 |
|
10 | 56% | 11 | 42% | |
|
7 | 39% | 10 | 38% | 0.4620 |
|
4 | 22% | 4 | 15% | |
|
2 | 11% | 2 | 8% | |
|
0 | 0% | 3 | 12% | |
|
2 | 11% | 0 | 0% | |
|
1 | 6% | 2 | 8% | |
|
1 | 6% | 0 | 0% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
0 | 0% | 1 | 4% | |
|
1 | 6% | 0 | 0% | |
Synchronous | 8 | 44% | 16 | 62% | 0.5343 |
Metachronous | 8 | 44% | 8 | 31% | |
No | 2 | 11% | 2 | 7% | |
None | 9 | 50% | 17 | 65% | 0.3613 |
Yes | 9 | 50% | 9 | 35% | |
Lung | 3 | 17% | 3 | 12% | 0.6025 |
Bone | 1 | 6% | 2 | 8% | |
Kidney | 1 | 6% | 1 | 4% | |
Lung + bone + brain | 1 | 6% | 0 | 0% | |
Bone + peritoneum | 1 | 6% | 0 | 0% | |
Pleural + bone | 1 | 6% | 0 | 0% | |
Retroperineal | 1 | 6% | 0 | 0% | |
Adrenal gland | 0 | 0% | 1 | 4% | |
Lymphnode | 0 | 0% | 1 | 4% | |
Bone + lymphnode | 0 | 0% | 1 | 4% | |
Systemic therapy | 16 | 89% | 26 | 100% | 0.1617 |
Liver surgery | 4 | 22% | 12 | 46% | 0.1251 |
Local treatments | 11 | 61% | 8 | 31% | 0.0657 |
TACE | 8 | 43% | 4 | 15% | 0.1529 |
TACE+RFA | 1 | 6% | 0 | 0% | |
TACE+CP | 1 | 6% | 0 | 0% | |
TACE/MWA/CRYOTH | 0 | 0% | 2 | 8% | |
CRYOTH | 1 | 6% | 0 | 0% | |
IBT | 0 | 0% | 2 | 8% | |
Cardiac diseases | 6 | 33% | 7 | 27% | 0.7422 |
Pulmonary diseases | 3 | 17% | 7 | 27% | 0.4889 |
Liver diseases | 9 | 50% | 0 | 0% | <0.0001 |
1 | 15 | 83% | 21 | 81% | 1.000 |
2 | 3 | 17% | 5 | 19% |
Characteristics of target lesions in the 2 groups
LESIONS | i.v. pECT (N = 21) | i.a. pEC (N = 31) | P value | ||
---|---|---|---|---|---|
N | % | N | % | ||
Hypervascular | 2 | 9.5% | 5 | 16.1% | 0.7664 |
Intermediate | 14 | 66.7% | 20 | 64.5% | |
Hypovascular | 5 | 23.8% | 6 | 19.4% | |
Yes | 19 | 90.5% | 21 | 67.7% | 0.0927 |
No | 2 | 9.5% | 10 | 32.3% | |
Distant (> 10 mm) | 4 | 19.0% | 8 | 25.8% | 0.5389 |
Close (1 mm to 10 mm) | 6 | 28.6% | 5 | 16.1% | |
Adjacent (< 1 mm) | 11 | 52.4% | 18 | 58.1% | |
Yes | 7 | 33.3% | 8 | 25.8% | 0.7559 |
No | 14 | 66.7% | 23 | 74.2% | |
TACE (transarterial chemoembolization) | 6 | 28.6% | 4 | 12.9% | 0.1474 |
CP (chemoperfusion) | 1 | 4.8% | 0 | 0.0% | |
IBT (interstitial brachytherapy) | 0 | 0.0% | 2 | 6.5% | |
TACE/MWA/CRYOTH | 0 | 0.0% | 2 | 6.5% | |
Yes | 20 | 95.2% | 31 | 100.0% | 0.2199 |
No | 1 | 4.8% | 0 | 0.0% |